200 related articles for article (PubMed ID: 15044431)
1. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.
Kartsonis NA; Saah A; Lipka CJ; Taylor A; Sable CA
J Antimicrob Chemother; 2004 May; 53(5):878-81. PubMed ID: 15044431
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
3. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin: a review of its use in the treatment of fungal infections.
McCormack PL; Perry CM
Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
9. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin--a new therapeutic option for oropharyngeal candidiasis.
Garbino J
Clin Microbiol Infect; 2004 Mar; 10(3):187-9. PubMed ID: 15008939
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin for the treatment of less common forms of invasive candidiasis.
Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
[TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin.
Keating GM; Jarvis B
Drugs; 2001; 61(8):1121-9; discussion 1130-1. PubMed ID: 11465873
[TBL] [Abstract][Full Text] [Related]
15. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.
Pelletier R; Alarie I; Lagacé R; Walsh TJ
Med Mycol; 2005 Sep; 43(6):559-64. PubMed ID: 16320498
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.
Arathoon EG; Gotuzzo E; Noriega LM; Berman RS; DiNubile MJ; Sable CA
Antimicrob Agents Chemother; 2002 Feb; 46(2):451-7. PubMed ID: 11796357
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.
Maschmeyer G; Glasmacher A
Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
